IN157856B - - Google Patents

Info

Publication number
IN157856B
IN157856B IN113/CAL/83A IN113CA1983A IN157856B IN 157856 B IN157856 B IN 157856B IN 113CA1983 A IN113CA1983 A IN 113CA1983A IN 157856 B IN157856 B IN 157856B
Authority
IN
India
Application number
IN113/CAL/83A
Other languages
English (en)
Inventor
Julien Pierre Henri Verheyden
John Charles Martin
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Priority to IN522/MAS/85A priority Critical patent/IN162289B/en
Priority to IN521/MAS/85A priority patent/IN162275B/en
Publication of IN157856B publication Critical patent/IN157856B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1786—Unsaturated ethers containing hydroxy or O-metal groups containing halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN113/CAL/83A 1982-02-01 1983-01-31 IN157856B (cg-RX-API-DMAC7.html)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN522/MAS/85A IN162289B (cg-RX-API-DMAC7.html) 1982-02-01 1985-07-10
IN521/MAS/85A IN162275B (cg-RX-API-DMAC7.html) 1982-02-01 1985-07-10

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34470382A 1982-02-01 1982-02-01
US07/451,262 US5250535A (en) 1982-02-01 1982-12-22 Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent

Publications (1)

Publication Number Publication Date
IN157856B true IN157856B (cg-RX-API-DMAC7.html) 1986-07-12

Family

ID=26994067

Family Applications (1)

Application Number Title Priority Date Filing Date
IN113/CAL/83A IN157856B (cg-RX-API-DMAC7.html) 1982-02-01 1983-01-31

Country Status (20)

Country Link
US (1) US5250535A (cg-RX-API-DMAC7.html)
EP (1) EP0085424A3 (cg-RX-API-DMAC7.html)
KR (1) KR890000191B1 (cg-RX-API-DMAC7.html)
AU (2) AU572777B2 (cg-RX-API-DMAC7.html)
BR (1) BR8300475A (cg-RX-API-DMAC7.html)
DD (1) DD206781A5 (cg-RX-API-DMAC7.html)
DK (1) DK29183A (cg-RX-API-DMAC7.html)
ES (1) ES8504194A1 (cg-RX-API-DMAC7.html)
FI (1) FI79851C (cg-RX-API-DMAC7.html)
GR (1) GR81321B (cg-RX-API-DMAC7.html)
HU (1) HU193874B (cg-RX-API-DMAC7.html)
IL (1) IL67791A0 (cg-RX-API-DMAC7.html)
IN (1) IN157856B (cg-RX-API-DMAC7.html)
NO (1) NO161372C (cg-RX-API-DMAC7.html)
NZ (1) NZ203128A (cg-RX-API-DMAC7.html)
PH (5) PH19203A (cg-RX-API-DMAC7.html)
PL (1) PL140556B1 (cg-RX-API-DMAC7.html)
PT (1) PT76149B (cg-RX-API-DMAC7.html)
RO (3) RO89143A (cg-RX-API-DMAC7.html)
ZW (1) ZW2583A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR76891B (cg-RX-API-DMAC7.html) * 1981-08-11 1984-09-04 Wellcome Found
US4816447A (en) * 1981-08-26 1989-03-28 Merck & Co., Inc. Anti-viral guanine compounds
US4544634A (en) * 1982-10-14 1985-10-01 Burroughs Wellcome Co. Method of producing acyclovir
ZW22283A1 (en) * 1982-10-14 1985-05-22 Wellcome Found Antiviral compounds
US4609662A (en) * 1982-10-14 1986-09-02 Burroughs Wellcome Co. Method for using purine derivatives
US4880820A (en) * 1983-06-24 1989-11-14 Merck & Co., Inc. Guanine derivatives
EP0138683A3 (en) * 1983-09-30 1988-01-20 Merck & Co. Inc. Purine derivatives, their application in anti-viral compositions
US4897479A (en) * 1983-09-30 1990-01-30 Merck & Co., Inc. Arylsulfonyloxy purine intermediates
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
IL73682A (en) * 1983-12-20 1991-08-16 Medivir Ab Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
DE3571810D1 (en) * 1984-01-26 1989-08-31 Merck & Co Inc Substituted butyl guanines and their utilization in antiviral compositions
US4579849A (en) * 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
WO1986000901A1 (en) * 1984-07-20 1986-02-13 Gauntt Charles O Immunoregulatory and anti-viral compound
ES8705889A1 (es) * 1984-12-12 1987-06-01 Syntex Inc Un metodo para preparar eteres alcaximetilicos y esteres alcoximetilicos de derivados de guananina.
EP0206497B1 (en) * 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation
DE3627024A1 (de) * 1985-09-24 1987-04-02 Hoechst Ag In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
US4966895A (en) * 1989-02-02 1990-10-30 Merck & Co. Inc. Cyclic monophosphates of purine and pyrimidine acyclonucleosides as anti-retroviral agents
US5216142A (en) * 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5565565A (en) * 1994-08-04 1996-10-15 Syntex (U.S.A.) Inc. Preparation of N-9 substituted guanine compounds
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4347360A (en) * 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
GR76891B (cg-RX-API-DMAC7.html) * 1981-08-11 1984-09-04 Wellcome Found
NZ201662A (en) * 1981-08-26 1986-07-11 Merck & Co Inc 9-(1,3-(and 2,3)-dihydroxy-1-(and 2)-propoxy-methyl)guanine derivatives and methods for their preparation
US4816447A (en) * 1981-08-26 1989-03-28 Merck & Co., Inc. Anti-viral guanine compounds

Also Published As

Publication number Publication date
PT76149A (en) 1983-02-01
NO161372C (no) 1989-08-09
PH20360A (en) 1986-12-04
FI79851C (fi) 1990-03-12
PH22817A (en) 1989-01-19
RO89143A (ro) 1986-04-30
EP0085424A2 (en) 1983-08-10
AU572777B2 (en) 1988-05-19
PL240367A1 (en) 1985-10-08
RO86234B (ro) 1985-03-31
NZ203128A (en) 1987-08-31
NO830316L (no) 1983-08-02
FI830254A0 (fi) 1983-01-26
DK29183D0 (da) 1983-01-25
PT76149B (en) 1985-11-25
PH22824A (en) 1989-01-19
ES519423A0 (es) 1985-04-16
US5250535A (en) 1993-10-05
ZW2583A1 (en) 1983-05-11
RO86234A (ro) 1985-03-15
AU1096183A (en) 1983-08-11
PH19203A (en) 1986-01-31
AU1261488A (en) 1988-06-02
KR890000191B1 (ko) 1989-03-10
HU193874B (en) 1987-12-28
DD206781A5 (de) 1984-02-08
ES8504194A1 (es) 1985-04-16
FI79851B (fi) 1989-11-30
EP0085424A3 (en) 1984-07-18
KR840003253A (ko) 1984-08-20
RO89142A (ro) 1986-04-30
PL140556B1 (en) 1987-05-30
FI830254L (fi) 1983-08-02
IL67791A0 (en) 1983-05-15
GR81321B (cg-RX-API-DMAC7.html) 1984-12-11
DK29183A (da) 1983-08-02
BR8300475A (pt) 1983-11-01
PH20099A (en) 1986-09-24
NO161372B (no) 1989-05-02

Similar Documents

Publication Publication Date Title
CH655644B (cg-RX-API-DMAC7.html)
CH650894GA3 (cg-RX-API-DMAC7.html)
CH655392B (cg-RX-API-DMAC7.html)
DE3348027A1 (cg-RX-API-DMAC7.html)
FR2519822B1 (cg-RX-API-DMAC7.html)
FR2519958B1 (cg-RX-API-DMAC7.html)
FR2519260B3 (cg-RX-API-DMAC7.html)
CH655487B (cg-RX-API-DMAC7.html)
DE3382599D1 (cg-RX-API-DMAC7.html)
CH670182GA3 (cg-RX-API-DMAC7.html)
DE3375853T2 (cg-RX-API-DMAC7.html)
CH655441B (cg-RX-API-DMAC7.html)
FR2520114B1 (cg-RX-API-DMAC7.html)
CH675516GA3 (cg-RX-API-DMAC7.html)
FR2520279B1 (cg-RX-API-DMAC7.html)
FR2520123B1 (cg-RX-API-DMAC7.html)
FR2519812B2 (cg-RX-API-DMAC7.html)
FR2519809B1 (cg-RX-API-DMAC7.html)
CH655536B (cg-RX-API-DMAC7.html)
CH655572B (cg-RX-API-DMAC7.html)
FR2520063B3 (cg-RX-API-DMAC7.html)
FR2519914B3 (cg-RX-API-DMAC7.html)
FR2519673B1 (cg-RX-API-DMAC7.html)
FR2519745B3 (cg-RX-API-DMAC7.html)
FR2520019B1 (cg-RX-API-DMAC7.html)